Free Trial
NASDAQ:CHRS

Coherus Oncology (CHRS) Stock Price, News & Analysis

Coherus Oncology logo
$1.18 +0.05 (+3.98%)
As of 10:53 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Coherus Oncology Stock (NASDAQ:CHRS)

Key Stats

Today's Range
$1.13
$1.20
50-Day Range
$0.72
$1.13
52-Week Range
$0.66
$2.43
Volume
553,514 shs
Average Volume
1.67 million shs
Market Capitalization
$136.57 million
P/E Ratio
0.76
Dividend Yield
N/A
Price Target
$4.68
Consensus Rating
Moderate Buy

Company Overview

Coherus Oncology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
79th Percentile Overall Score

CHRS MarketRank™: 

Coherus Oncology scored higher than 79% of companies evaluated by MarketBeat, and ranked 219th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Coherus Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Coherus Oncology has received no research coverage in the past 90 days.

  • Read more about Coherus Oncology's stock forecast and price target.
  • Earnings Growth

    Earnings for Coherus Oncology are expected to grow in the coming year, from ($1.05) to ($0.67) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Coherus Oncology is 0.73, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.06.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Coherus Oncology is 0.73, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 30.40.

  • Price to Book Value per Share Ratio

    Coherus Oncology has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Coherus Oncology's valuation and earnings.
  • Percentage of Shares Shorted

    30.35% of the float of Coherus Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Coherus Oncology has a short interest ratio ("days to cover") of 23.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Coherus Oncology has recently increased by 3.55%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Coherus Oncology does not currently pay a dividend.

  • Dividend Growth

    Coherus Oncology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    30.35% of the float of Coherus Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Coherus Oncology has a short interest ratio ("days to cover") of 23.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Coherus Oncology has recently increased by 3.55%, indicating that investor sentiment is decreasing.
  • Search Interest

    Only 1 people have searched for CHRS on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Coherus Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Coherus Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $73,991.00 in company stock.

  • Percentage Held by Insiders

    Only 8.08% of the stock of Coherus Oncology is held by insiders.

  • Percentage Held by Institutions

    72.82% of the stock of Coherus Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Coherus Oncology's insider trading history.
Receive CHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coherus Oncology and its competitors with MarketBeat's FREE daily newsletter.

CHRS Stock News Headlines

I trusted Trump and got screwed
Porter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning about a dangerous flaw in America’s financial system for 15 years, he believed Trump might fix it. Instead, he says the problem has only grown worse. In his new emergency broadcast, Breaking Point, Porter reveals why this flaw may now be irreversible—and how it could gut retirement accounts, trigger mass wealth destruction, and blindside hard-working investors.tc pixel
Coherus Oncology: Q2 Earnings Snapshot
Coherus (CHRS) Q2 Revenue Jumps 10%
See More Headlines

CHRS Stock Analysis - Frequently Asked Questions

Coherus Oncology's stock was trading at $1.38 at the beginning of the year. Since then, CHRS shares have decreased by 18.1% and is now trading at $1.13.

Coherus Oncology, Inc. (NASDAQ:CHRS) posted its quarterly earnings results on Monday, May, 12th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.04. The biotechnology company had revenue of $7.60 million for the quarter, compared to analyst estimates of $59.79 million.
Read the conference call transcript
.

The following companies are subsidiaries of Coherus Oncology: InteKrin, Coherus Intermediate Corp, InteKrin Russia, and InteKrin Therapeutics Inc..

Coherus Oncology's top institutional shareholders include Geode Capital Management LLC (2.31%), Rubric Capital Management LP (0.75%), Panagora Asset Management Inc. (0.69%) and Tejara Capital Ltd (0.60%). Insiders that own company stock include Dennis M Lanfear and Mats Wahlstrom.
View institutional ownership trends
.

Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Coherus Oncology investors own include Voyager Therapeutics (VYGR), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), Humana (HUM) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
5/12/2025
Today
8/21/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CHRS
CIK
1512762
Fax
N/A
Employees
330
Year Founded
2010

Price Target and Rating

High Price Target
$7.00
Low Price Target
$1.05
Potential Upside/Downside
+314.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
$1.55
Trailing P/E Ratio
0.73
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$28.51 million
Net Margins
125.90%
Pretax Margin
41.42%
Return on Equity
N/A
Return on Assets
-34.85%

Debt

Debt-to-Equity Ratio
0.31
Current Ratio
1.44
Quick Ratio
1.43

Sales & Book Value

Annual Sales
$266.96 million
Price / Sales
0.49
Cash Flow
$0.31 per share
Price / Cash Flow
3.67
Book Value
$1.03 per share
Price / Book
1.10

Miscellaneous

Outstanding Shares
116,230,000
Free Float
106,836,000
Market Cap
$131.34 million
Optionable
Optionable
Beta
0.89

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:CHRS) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners